Home Drug Guide Anileridine Hydrochloride

Drug Guide

Generic Name

Anileridine Hydrochloride

Brand Names Leritine

Classification

Therapeutic: Analgesic (Pain relief)

Pharmacological: Opioid analgesic (NRI) - Norepinephrine Reuptake Inhibitor)

FDA Approved Indications

Short-term management of moderate to severe pain

Mechanism of Action

Anileridine is an opioid analgesic that binds to opioid receptors in the central nervous system, inhibiting ascending pain pathways, altering the perception of and response to pain.

Dosage and Administration

Adult: Typically 50-100 mg IV or IM every 3-4 hours as needed, not exceeding 600 mg/day.

Pediatric: Limited data; use with caution, dosing similar to adult, adjusted for age and weight.

Geriatric: Use with caution; start at lower end of dosing range due to increased sensitivity.

Renal Impairment: Adjust dose carefully, monitoring for accumulation.

Hepatic Impairment: Use with caution; reduced metabolism may prolong effects.

Pharmacokinetics

Absorption: Complete absorption via IM or IV routes.

Distribution: Widely distributed; crosses blood-brain barrier.

Metabolism: Liver primarily metabolizes; small portion excreted unchanged.

Excretion: Renal excretion of metabolites.

Half Life: Approximately 2-3 hours.

Contraindications

Hypersensitivity to anileridine or opioids.
Severe respiratory depression.

Precautions

Use with caution in patients with respiratory depression, increased intracranial pressure, or head trauma.
Potential for dependence, abuse, and misuse.

Adverse Reactions - Common

Drowsiness, sedation (Common)
Nausea, vomiting (Common)
Dizziness (Common)

Adverse Reactions - Serious

Respiratory depression (Rare but serious)
Addiction, overdose (Serious)
Hypotension (Less common)

Drug-Drug Interactions

CNS depressants (e.g., alcohol, sedatives), potentiating sedation and respiratory depression.
MAO inhibitors may increase effects or prolong analgesia.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor respiratory rate, consciousness, and pain levels.

Diagnoses:

Risk for respiratory depression
Impaired comfort related to pain

Implementation: Administer IV/IM as prescribed, monitor vital signs closely.

Evaluation: Assess pain relief and respiratory status regularly.

Patient/Family Teaching

Do not operate heavy machinery or drive until effects are known.
Caution against alcohol and sedative use due to increased risk of respiratory depression.
Report symptoms of difficulty breathing or excessive sedation immediately.

Special Considerations

Black Box Warnings:

Risk of respiratory depression, addiction, and overdose.

Genetic Factors: Not specifically noted in guidelines.

Lab Test Interference: May affect liver function tests; interpret with caution.

Overdose Management

Signs/Symptoms: Respiratory depression, pinpoint pupils, extreme sedation, possible coma.

Treatment: Administer opioid antagonist (naloxone) immediately; provide supportive respiratory care.

Storage and Handling

Storage: Store at room temperature, protected from light and moisture.

Stability: Stable under recommended storage conditions for the period specified in the product labeling.